Breviscapin [123] reduces inflammatory factors by killing TLR4/NF-κB signaling pathway, which can reduce liver fibrosis by decreasing apoptotic response, blocking oxidative stress, and inhibiting inflammation. Here, TLR4 is linked to Hepatic fibrosis.